Advancing Oncology: SNMMI 2024 and ASCO 2024 Poster Presentations
Reflecting on the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Toronto, we are proud to have shared our poster presentations over the past month. This follows the recent success of our poster presentation at ASCO 2024 in Chicago, where we explored the correlation between ctDNA and radiographic imaging features in patients with metastatic melanoma undergoing immunotherapy. This collaboration between ACQI researchers, clinicians, and industry partner AIQ Solutions highlights the potential of international teamwork in oncology research. By harnessing the power of interdisciplinary collaboration and cutting-edge technology, we strive to shape the future of cancer treatment.
Click on the images to open an expanded version in a new tab.
ASCO 2024: “Correlation of ctDNA and radiographic imaging features derived from 18F-FDG PET/CT for patients with metastatic melanoma treated with immunotherapy”
In our ASCO 2024 poster, we delved into the relationship between blood biomarkers and radiographic imaging in metastatic melanoma. Retrospectively analysing 18F-FDG PET/CT scans from patients with metastatic melanoma receiving immunotherapy, we identified notable correlations between imaging features and ctDNA parameters, particularly in patients with BRAF mutations.
SNMMI 2024: “Radiotracer Generalizability: CNN Automated Detection in PSMA PET/CT – A Multi-Tracer Pilot Study in 68Ga-PSMA-11,18F-DCFPyL and 18F-PSMA-1007”
Our SNMMI poster focused on the fusion of artificial intelligence and medical imaging in metastatic prostate cancer management. Leveraging PSMA PET/CT imaging, we evaluated the performance of a convolutional neural network model across diverse radiotracers, including 68Ga-PSMA-11, 18F-DCFPyL, and 18F-PSMA-1007. Preliminary findings indicated high sensitivity and potential generalisability across different PSMA tracers, laying the groundwork for enhanced patient care.
Australian Centre for Quantitative Imaging 